LILLY AND CO news, videos and press releases
For more news please use our advanced search feature.
LILLY AND CO - More news...
LILLY AND CO - More news...
- Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
- DoH Collaborates with Eli Lilly and World Obesity Federation on Obesity Prevention and Management
- Thinking about trading options or stock in Intuit, Pinterest, Adobe, Eli Lilly, or Robinhood Markets?
- More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
- Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care
- Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
- Lilly to Participate in Cowen's 44th Annual Health Care Conference
- Philip Johnson to Retire as Lilly Treasurer
- Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP?
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
- Thinking about trading options or stock in General Motors, Meta Platforms, Archer-Daniels-Midland, Eli Lilly, or Celestica?
- Johna Norton to Retire as Lilly Executive Vice President of Global Quality
- Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
- Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance
- Thinking about trading options or stock in TG Therapeutics, Microsoft, Eli Lilly And Co, Chevron, or Alcon?
- Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™
- Lilly to Participate in J.P. Morgan Healthcare Conference
- Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences?
- Lilly Completes Acquisition of POINT Biopharma
- Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
- Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
- Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
- Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend
- Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium
- Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
- Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
- Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
- Thinking about trading options or stock in Eli Lilly And Co, Apple, Uber Technologies, Pure Storage, or Salesforce?
- Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego
